SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Fellous A, Ohayon R, Vacassin T, et al. Biochemical effects of Navelbine on tubulin and associated proteins. Semin Oncol. 1989; 16 (2 suppl 4 ): 914.
  • 2
    Mathe G, Reizenstein P. Phase I pharmacologic study of a new Vinca alkaloid: navelbine. Cancer Lett. 1985; 27: 285293.
  • 3
    Hohneker JA. A summary of vinorelbine (Navelbine) safety data from North American clinical trials. Semin Oncol. 1994; 21: 4247.
  • 4
    Budman DR. Vinorelbine (Navelbine): a third-generation vinca alkaloid. Cancer Invest. 1997; 15: 475490.
  • 5
    Madden T, Bleyer A, Hohneker J, Johansen MJ, Wargin W, Reaman G. The pharmacokinetics of vinorelbine (Navelbine) in pediatric cancer patients [abstract]. Proc Am Soc Clin Oncol. 1995; 14.
  • 6
    Sørensen JB. Current position of vinorelbine in cancer chemotherapy. Ann Oncol. 1995; 6: 105107.
  • 7
    Fidias P, Demetri G, Harmon DC. Navelbine shows activity in previously treated sarcoma patients: phase II results from MGH/DANA Farber/Partner's Cancer Care Study [abstract]. Proc Am Soc Clin Oncol. 1998; 17: 168a.
  • 8
    Nasti G, Errante D, Talamini R, et al. Vinorelbine is an effective and safe drug for AIDS-related Kaposi's sarcoma: results of a phase II study. J Clin Oncol. 2000; 18: 15501557.
  • 9
    Epelman S, Aguiar S, Silva A, et al. Phase II study of vinorelbine in children and adolescents with refractory or recurrent cancer [abstract]. Med Pediatr Oncol. 1997; 29: 338.
  • 10
    Epelman S, Aguiar S, Melaragno R, et al. High response rate of vinorelbine in children and adolescents with refractory or recurrent rhabdomyosarcomas or other sarcomas [abstract]. Med Pediatr Oncol. 1999; 33: 147:227.
  • 11
    National Cancer Institute. NCI common toxicity criteria, version 1. Investigator's handbook: a manual of participants in clinical trials of investigational agents sponsored by the Division of Cancer Treatment, National Cancer Institute. Bethesda, MD, U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, October 1993.
  • 12
    Raney RB, Anderson JR, Barr FG, et al. Rhabdomyosarcoma and undifferentiated sarcoma in the first decades of life: a selective review of Intergroup Rhabdomyosarcoma Study Group experience and rationale for Intergroup Rhabdomyosarcoma Study V. J Pediatr Hematol Oncol. 2001; 23: 215220.
  • 13
    Crist WM, Anderson JR, Meza JL, et al. Intergroup Rhabdomyosarcoma Study-IV: results for patients with nonmetastatic disease. J Clin Oncol. 2001; 19: 30913102.
  • 14
    Pappo AS, Etcubanas E, Santana VM, et al. A phase II trial of ifosfamide in previously untreated children and adolescents with unresectable rhabdomyosarcoma. Cancer. 1993; 71: 21192125.
  • 15
    Horowitz ME, Etcubanas E, Christensen ML, et al. Phase II testing melphalan in children with newly diagnosed rhabdomyosarcoma: a model for anticancer drug development. J Clin Oncol. 1988; 6: 308314.
  • 16
    Nitschke R, Parkhurst J, Sullivan J, Harris MB, Bernstein M, Pratt C. Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group phase II study. J Pediatr Hematol Oncol. 1998; 20: 315318.
  • 17
    Pappo AS, Lyden E, Breneman J, et al. Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: an Intergroup Rhabdomyosarcoma Study. J Clin Oncol. 2001; 19: 213219.
  • 18
    Smith MA, Anderson B. Phase II window studies: 10 years of experience and counting. J Pediatr Hematol Oncol. 2001; 23: 334337.